Evaxion A (EVAX) Other Non-Current Liabilities (2021 - 2025)
Evaxion A (EVAX) reported Other Non-Current Liabilities of $158000.0 for Q4 2025, up 12.06% on a YoY basis from $141000.0 in Q4 2024, and little changed quarter-over-quarter from $158000.0 in Q2 2025.
Evaxion A (EVAX) Other Non-Current Liabilities (2021 - 2025) Analysis & Trends
Evaxion A has reported Other Non-Current Liabilities for 5 years, with the latest figure at $158000.0 in Q4 2025.
- For the quarter ending Q4 2025, Other Non-Current Liabilities rose 12.06% year-over-year to $158000.0; the trailing twelve-month figure through Dec 2025 stood at $158000.0 (up 12.06% YoY), and the FY2025 full-year result was $158000.0, up 12.06% from the prior year.
- Other Non-Current Liabilities for Q4 2025 stood at $158000.0, roughly flat from $158000.0 in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $573000.0 in Q4 2022, with the low at $52000.0 in Q1 2021.
- Historically, Other Non-Current Liabilities has averaged $167461.5 across 5 years, with a median of $149000.0 in 2023.
- Annual changes were most pronounced in 2022 — Other Non-Current Liabilities soared 274.51% — and 2023, when it slumped 74.0%.
- Evaxion A's Other Non-Current Liabilities stood at $153000.0 in 2021, then soared by 274.51% to $573000.0 in 2022, then tumbled by 74.0% to $149000.0 in 2023, then retreated by 5.37% to $141000.0 in 2024, then grew by 12.06% to $158000.0 in 2025.
- The last three Other Non-Current Liabilities figures came in at $158000.0 (Q4 2025), $158000.0 (Q2 2025), and $141000.0 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Regeneron Pharmaceuticals | 63.43 Bn | 54.67 Bn | 3.31 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 158,000.00 |
| Jun 30, 2025 | 158,000.00 |
| Dec 31, 2024 | 141,000.00 |
| Jun 30, 2024 | 145,000.00 |
| Dec 31, 2023 | 149,000.00 |
| Jun 30, 2023 | 147,000.00 |
| Dec 31, 2022 | 573,000.00 |
| Jun 30, 2022 | 141,000.00 |
| Mar 31, 2022 | 150,000.00 |
| Dec 31, 2021 | 153,000.00 |
| Sep 30, 2021 | 157,000.00 |
| Jun 30, 2021 | 53,000.00 |
| Mar 31, 2021 | 52,000.00 |